Live Analyst Rating Changes 34067 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Tazeen Ahmad
BofA

Tazeen Ahmad

Wall Street Analyst
★★☆☆☆
#2302
on 13Foresight · ranked by our own returns
50%
Success Rate
-1.9%
Average Return
75 of 150 calls profitable · +16.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 50% of Tazeen Ahmad's ratings turned a profit when each position was held for 1 year — averaging -1.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

281 Buy 31 Hold 41 Sell
Tazeen's Stock Coverage 60 ratings · 2026-09-24
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
VRTX
Vertex Pharmaceuticals
Sep 22, 2026 BUY Strong Buy
-14.2% avg upside
62 analysts
$672.00
30.09% Upside
· ·
AMGN
Amgen
Sep 22, 2026 SELL Buy
-21.3% avg upside
57 analysts
$317.00
21.95% Downside
-0.0% ·
ARGX
Argenx Se
Sep 21, 2026 BUY Strong Buy
-12.6% avg upside
48 analysts
$1136.00
20.15% Upside
· ·
RARE
Ultragenyx Pharmaceutical
Sep 18, 2026 HOLD Strong Buy
+235.0% avg upside
36 analysts
$20.00
34.47% Upside
+1.2% ·
SRRK
Scholar Rock Holding
Sep 16, 2026 BUY Strong Buy
+31.1% avg upside
23 analysts
$72.00
44.47% Upside
+1.0% ·
PBLS
Parabilis Medicines, Inc.
Sep 16, 2026 BUY Strong Buy
+31.0% avg upside
6 analysts
$45.00
35.13% Upside
+13.2% ·
ASND
Ascendis Pharma
Sep 15, 2026 BUY Strong Buy
+26.0% avg upside
26 analysts
$304.00
36.15% Upside
-1.3% ·
OCUL
Ocular Therapeutix
Sep 15, 2026 BUY Strong Buy
+144.2% avg upside
21 analysts
$27.00
169.97% Upside
-2.0% ·
DFTX
Definium Therapeutics
Sep 14, 2026 BUY Strong Buy
+39.2% avg upside
23 analysts
$91.00
141.69% Upside
-2.4% ·
KYMR
Kymera Therapeutics
Sep 14, 2026 BUY Strong Buy
-4.9% avg upside
37 analysts
$144.00
24.73% Upside
+2.6% ·
BNTX
BioNTech SE
Sep 14, 2026 BUY Strong Buy
+35.9% avg upside
26 analysts
$122.00
23.90% Upside
-0.4% ·
PHVS
Pharvaris
Sep 08, 2026 HOLD Strong Buy
+68.7% avg upside
15 analysts
$44.00
33.06% Upside
-4.8% ·
BLTE
Belite Bio, Inc. ADR
Sep 02, 2026 BUY Strong Buy
+18.4% avg upside
11 analysts
$200.00
18.57% Upside
+6.4% ·
ALNY
Alnylam Pharma
Aug 31, 2026 BUY Strong Buy
+28.7% avg upside
51 analysts
$346.00
40.35% Upside
+3.9% ·
PRTA
Prothena
Aug 14, 2026 SELL Buy
+188.1% avg upside
14 analysts
— +3.8% ·
AARD
Aardvark Therapeutics, Inc.
Aug 14, 2026 SELL Buy
+247.5% avg upside
12 analysts
— +15.0% ·
ANRO
Alto Neuroscience, Inc.
Aug 14, 2026 BUY Strong Buy
+13.7% avg upside
13 analysts
— -4.7% ·
IMMX
Immix Biopharma
Aug 14, 2026 BUY Strong Buy
+63.3% avg upside
9 analysts
— +14.0% ·
TSHA
Taysha Gene Therapies
Aug 14, 2026 BUY Strong Buy
+186.4% avg upside
22 analysts
— -14.9% ·
STRO
Sutro Biopharma
Aug 14, 2026 SELL Strong Buy
+162.3% avg upside
21 analysts
— +20.2% ·
PTCT
PTC Therapeutics
Aug 13, 2026 BUY Buy
+29.3% avg upside
29 analysts
$96.00
54.09% Upside
-9.2% ·
ANNX
Annexon Biosciences
Aug 12, 2026 BUY Strong Buy
+260.9% avg upside
14 analysts
$8.00
106.76% Upside
-20.6% ·
BCAX
Bicara Therapeutics Inc.
Aug 11, 2026 BUY Strong Buy
+58.3% avg upside
16 analysts
$34.00
65.91% Upside
-4.7% ·
DNLI
Denali Therapeutics
Aug 07, 2026 BUY Strong Buy
+89.0% avg upside
24 analysts
$31.00
51.48% Upside
-17.6% ·
PEPG
PepGen Inc.
Aug 07, 2026 SELL Strong Buy
+283.7% avg upside
9 analysts
$2.50
8.15% Downside
-0.0% ·
FULC
Fulcrum Therapeutics
Aug 07, 2026 SELL Buy
+161.9% avg upside
14 analysts
$3.00
21.32% Downside
+3.3% ·
ARVN
Arvinas Holding Company
Aug 07, 2026 HOLD Buy
+254.7% avg upside
28 analysts
— -5.3% ·
SRPT
Sarepta Therapeutics
Aug 06, 2026 SELL Buy
+217.8% avg upside
49 analysts
$18.00
5.10% Downside
-19.9% ·
ACAD
ACADIA Pharmaceuticals
Aug 05, 2026 BUY Strong Buy
+44.8% avg upside
43 analysts
$31.00
21.92% Upside
-7.0% ·
GILD
Gilead Sciences
Aug 05, 2026 BUY Strong Buy
-22.0% avg upside
66 analysts
$162.00
7.03% Upside
+15.8% ·
RYTM
Rhythm Pharmaceuticals
Aug 04, 2026 BUY Strong Buy
+25.8% avg upside
22 analysts
$149.00
51.69% Upside
-7.1% ·
REGN
Regeneron
Jul 30, 2026 BUY Strong Buy
-1.6% avg upside
58 analysts
$891.00
11.11% Upside
+8.2% ·
NBIX
Neurocrine
Jul 30, 2026 BUY Strong Buy
+34.0% avg upside
37 analysts
$214.00
53.37% Upside
-21.2% ·
INCY
Incyte
Jul 28, 2026 BUY Buy
-12.6% avg upside
48 analysts
$140.00
12.26% Upside
-4.7% ·
BCRX
BioCryst
Jul 15, 2026 BUY Strong Buy
+110.7% avg upside
24 analysts
$15.00
75.05% Upside
-7.8% ·
GB:0QW0
arGEN X
Jul 02, 2026 BUY Strong Buy
-25.7% avg upside
25 analysts
— · ·
FATE
Fate Therapeutics
May 21, 2026 HOLD Buy
+382.1% avg upside
31 analysts
$2.20
9.54% Downside
+20.5% ·
NMRA
Neumora Therapeutics, Inc.
Apr 01, 2025 SELL Buy
+949.2% avg upside
11 analysts
$1.00
36.74% Upside
-128.9% ·
FDMT
4D Molecular Therapeutics
Sep 19, 2024 BUY Strong Buy
+124.7% avg upside
16 analysts
$79.00
426.70% Upside
-51.1% ·
ADCT
ADC Therapeutics
Oct 17, 2023 SELL Buy
+301.0% avg upside
12 analysts
$1.00
23.59% Downside
-309.9% ·
OBX
Obsidian Therapeutics
Aug 11, 2023 SELL Strong Buy
+12.9% avg upside
11 analysts
$0.50
96.72% Downside
· ·
PYXS
Pyxis Oncology
May 24, 2023 HOLD Strong Buy
+150.4% avg upside
15 analysts
$4.00
24.21% Upside
+14.1% ·
PRLD
Prelude Therapeutics
Mar 27, 2023 SELL Buy
+139.0% avg upside
7 analysts
$6.00
39.12% Upside
+23.9% ·
PRAX
Praxis Precision Medicines
Mar 06, 2023 HOLD Strong Buy
+95.4% avg upside
24 analysts
$22.50
92.10% Downside
· ·
SQZB
SQZ Biotechnologies
Dec 01, 2022 SELL Strong Buy
+102677.7% avg upside
7 analysts
$20.00
83233.28% Upside
· ·
SRZN
Surrozen
Nov 16, 2022 SELL Strong Buy
+108.7% avg upside
8 analysts
$1.00
93.87% Downside
+66.9% ·
TBPH
Theravance Biopharma
Apr 19, 2022 SELL Hold
+8.3% avg upside
18 analysts
$9.00
47.13% Downside
-28.1% ·
KALA
KALA BIO
Jul 21, 2021 BUY Strong Buy
+37802.3% avg upside
9 analysts
$8.00
1328.50% Upside
· ·
MRNA
Moderna
Jan 25, 2021 HOLD Hold
-43.5% avg upside
38 analysts
$150.00
17.65% Downside
+3.8% ·
QNCX
Quince Therapeutics
Jun 03, 2019 HOLD Buy
+539.3% avg upside
17 analysts
$28.00
7.14% Downside
· ·
ALEC
Alector
Mar 04, 2019 BUY Hold
+395.8% avg upside
15 analysts
$26.00
1187.10% Upside
+50.2% ·
DBVT
DBV Technologies SA - American
Dec 20, 2018 SELL Strong Buy
+97.3% avg upside
15 analysts
$8.00
34.19% Downside
-66.5% ·
PCRX
Pacira Pharmaceuticals
Oct 10, 2018 HOLD Buy
+55.4% avg upside
22 analysts
$48.00
94.90% Upside
-19.3% ·
MCRB
Seres Therapeutics
Aug 03, 2018 SELL Buy
+332.6% avg upside
11 analysts
$6.00
58.30% Upside
· ·
ACET
Adicet Bio
Feb 20, 2018 BUY Strong Buy
+197.0% avg upside
14 analysts
$23.00
170.89% Upside
· ·
SPRO
Spero Therapeutics
Nov 27, 2017 HOLD Buy
+988.5% avg upside
12 analysts
$16.00
1169.85% Upside
-44.6% ·
RMTI
Rockwell Med
Nov 08, 2016 SELL Buy
+56.8% avg upside
11 analysts
$5.00
41.61% Downside
· ·
CORT
Corcept Therapeutics
Jun 02, 2016 SELL Buy
-41.0% avg upside
16 analysts
$5.00
95.49% Downside
-92.3% ·
INVA
Innoviva
Sep 09, 2015 SELL Buy
+40.1% avg upside
12 analysts
$13.00
35.70% Downside
-5.1% ·
GLNG
Golar LNG
Sep 19, 2014 BUY Strong Buy
-10.5% avg upside
22 analysts
$110.00
120.19% Upside
-50.2% ·
🔒 55 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Tazeen Ahmad — Frequently Asked Questions
How accurate are Tazeen Ahmad's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Tazeen's ratings were profitable over a one-year hold, with an average return of -1.9% per rating, or +16.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Tazeen ranked on 13Foresight?
Tazeen Ahmad is currently ranked #2302 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Tazeen cover?
Tazeen most recently has ratings on VRTX, AMGN, ARGX, RARE, SRRK, PBLS, ASND, OCUL, DFTX, KYMR, BNTX, PHVS and 48 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.